Menu

利伐沙班列入医保了吗?

Author: Medicalhalo
Release time: 2025-10-19 11:44:20

Rivaroxaban was jointly developed by Bayer Pharma of Germany and Johnson & Johnson of the United States. In October 2008, it was approved for marketing in Canada and the European Union under the trade name Xarelto.

Rivaroxaban is the world's first oral direct factor Xa inhibitor, which can highly selectively and competitively inhibit free and bound factor It has the characteristics of high bioavailability, wide spectrum of disease treatment, stable dose-effect relationship, convenient oral administration and low risk of bleeding.

Rivaroxaban is also a drug used to prevent and treat venous thrombosis. Clinically, it is mainly used to prevent the formation of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients after hip and knee replacement surgery. It can also be used to prevent stroke and non-central nervous system embolism in patients with non-valvular atrial fibrillation, and reduce the risk of recurrence of coronary syndrome.

So, is rivaroxaban included in medical insurance?

According to Medical Companion Travel, rivaroxaban tablets are covered by medical insurance. Rivaroxaban belongs to the National Medical Insurance Category B. The price of rivaroxaban in China is as follows: Domestic rivaroxaban is the original drug produced by Bayer Pharma AG/Germany Bayer Pharmaceuticals. Specification: 10mg-5 tablets/box, priced at about 138$; Specification: 15mg-7 tablets/box, priced at about 199$; Specification: 20mg-7 tablets/box, priced at about 263$.

The specifications of rivaroxaban available abroad are 15mg*28 tablets; the price of 20mg*28 tablets is around $600. For specific and detailed prices, you can consult Medical Companion Travel at any time! In terms of purchase, patients can go abroad to purchase from pharmacies or obtain them through domestic professional overseas medical service organizations (such as Medical Companion Travel).

Rivaroxaban is a highly selective, oral drug that directly inhibits factor xa. By inhibiting factor xa, the endogenous and exogenous pathways of the coagulation cascade can be interrupted, and the generation of thrombin and thrombosis can be inhibited.

[ 免责声明 ]  本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。